Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Bristol-Myers Squibb stock up 20%+ by Q1 2025 end post-Opdivo approval?  | Binary | 3 | 3 months ago | ||
Opdivo leading treatment for resectable NSCLC by end of 2025? | Binary | 2 | 3 months ago | ||
Significant NSCLC survival rate increase with Opdivo by 2025 end? | Binary | 2 | 3 months ago | ||
Next company to receive FDA approval for resectable NSCLC treatment by 2025 end? | Categorical | 2 | 3 months ago | ||
Most common side effect of Opdivo for NSCLC by 2025 end? | Categorical | 2 | 3 months ago | ||
Region with highest Opdivo adoption for NSCLC by 2025 end? | Categorical | 1 | 3 months ago |